Plunkett Research Online: Eidos Therapeutics Inc

EIDOS THERAPEUTICS INC (EIDX:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, incl.....



Eidos Therapeutics Inc
Ticker: EIDX
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 415 887-1471
Fax:
Address: 101 Montgomery Street
Suite 2550
San Francisco, CA 94104 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Pharmaceutical Preparation Manufacturing
ContactsDescription

Neil KumarCEO/Director
Christine SiuCFO/Chief Accounting Officer
See More
Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, incl.....See More See More

Auditor: ERNST & YOUNG, LLP
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201820172016
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: